Astellas Gene Therapies is making a renewed effort to tackle X-linked Myotubular Myopathy (XLMTM), a rare muscle-weakening condition. After facing setbacks in previous trials, the company is shifting its approach by collaborating with Kate Therapeutics to develop a new gene therapy using a MyoAAV capsid. This strategic partnership aims to enhance safety and efficacy compared to earlier gene therapy candidates.
Transitioning Strategies
The previous candidate, resamirigene bilparvovec (AT132), faced significant challenges, including the tragic loss of four boys during a Phase I/II trial. As a result, Astellas has pivoted to a different vector for gene delivery. By leveraging the capabilities of Kate Therapeutics, Astellas plans to develop KT430, or ASP2957, which utilizes a MyoAAV capsid. This innovative approach is intended to provide a safer therapeutic alternative.
Understanding MyoAAV Technology
ASP2957 is designed as a non-replicating recombinant adeno-associated virus (AAV) that incorporates the human MTM1 gene, controlled by an MHCK7 muscle-specific promoter. Richard Wilson, senior vice president at Astellas, emphasized that this new capsid technology allows for improved affinity and uptake of the viral vector into muscle cells. Consequently, this development aims to deliver lower doses of the gene therapy while achieving comparable levels of therapeutic protein production.
Enrollment in the VALOR Trial
In a significant move, Astellas has initiated the Phase I/II VALOR trial to assess the safety and efficacy of ASP2957 in boys diagnosed with XLMTM. This first-in-human study will involve a careful dose-escalation strategy to determine the optimal infusion for participants. The initial target is to enroll nine patients, with the hope of administering the first dose within the fiscal year.
Learning from Past Trials
The company is not resuming the previous ASPIRO trial due to the tragic outcomes associated with it. An internal investigation identified cholestatic tendencies in XLMTM patients, which may have played a role in the adverse events observed. Astellas is now focusing on understanding this condition better through a new observational study named EXCEL, which aims to map the prevalence and progression of cholestasis in affected individuals.
Expanding Capsid Research
Astellas is also actively pursuing advancements in capsid technology beyond its collaboration with Kate Therapeutics. The company has made significant strides in developing new capsids through partnerships with Sangamo Therapeutics and Dyno Therapeutics. These collaborations indicate Astellas’ commitment to enhancing gene therapy delivery mechanisms for treating neurological and muscular diseases.
Broader Gene Therapy Initiatives
Beyond XLMTM, Astellas is advancing several other gene therapy programs. AT845, aimed at treating late-onset Pompe disease, has completed its Phase I-II study, with a proof-of-concept decision anticipated soon. Additionally, the company is exploring AVB-101, a gene therapy for frontotemporal dementia, indicating a diverse and ambitious pipeline in genetic medicine.
Looking Ahead
Astellas is dedicated to innovating gene therapy solutions, particularly for conditions that currently lack effective treatments. Their ongoing research into DM1 and Angelman Syndrome reflects a broader commitment to addressing significant unmet medical needs in genetic disorders.
Key Takeaways
- Astellas is developing a new gene therapy for XLMTM in collaboration with Kate Therapeutics.
- The MyoAAV capsid aims to improve safety and reduce dosage requirements.
- The VALOR trial has commenced, focusing on dose optimization for ASP2957.
- Astellas is investing in partnerships to develop next-generation capsids and expand its gene therapy portfolio.
- Ongoing studies seek to better understand cholestatic conditions in XLMTM patients.
In summary, Astellas is embarking on a new chapter in gene therapy for XLMTM, leveraging innovative technologies and collaborations to enhance treatment safety and efficacy. Their proactive approach to learning from past experiences positions them well for future successes in the field of genetic medicine.
Read more → www.genengnews.com